US 12,275,794 B2
Bispecific antigen binding molecules comprising anti-FAP clone 212
Peter Bruenker, Hittanu (CH); Harald Duerr, Starnberg (DE); Christian Klein, Bonstetten (CH); Pablo Umana, Wollerau (CH); Alexander Bujotzek, Munich (DE); Joerg Zielonka, Bulach (CH); Christine Trumpfheller, Zurich (CH); Moritz Rapp, Zurich (CH); and Marine Le Clech, Schlieren (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,647.
Application 17/557,647 is a division of application No. 16/588,780, filed on Sep. 30, 2019, granted, now 11,242,396.
Claims priority of application No. 18197866 (EP), filed on Oct. 1, 2018.
Prior Publication US 2022/0227878 A1, Jul. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 1/16 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 1/16 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01)] 27 Claims
 
1. A method of treating an individual having a Fibroblast Activation Protein (FAP)-expressing cancer comprising administering to the individual an effective amount of a bispecific antigen binding molecule, comprising
(a) at least one antigen binding domain capable of specific binding to CD40, and
(b) at least one antigen binding domain capable of specific binding to FAP comprising a heavy chain variable region (VHFAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:3, (ii) CDR-H2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO: 11 and SEQ ID NO:12, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region (VLFAP) comprising (iv) CDR-L1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:13 and SEQ ID NO:14, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:7, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:8.